Last updated on May 2018

MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics

Brief description of study

Interventional, multicenter, open-label, 20 weeks study

  • To identify efficacy and safety in switching from oral aripiprazole to Abilify Maintena.
  • To identify efficacy and safety in switching from oral atypical antipsychotics other than aripiprazole to Abilify Maintena

Detailed Study Description

We would like to evaluate the efficacy and safety when switching to Abilify Maintena according to the approved indication of Abilify Maintena, for subjects who are taking oral antipsychotic drugs. It is expected that this will serve as a basis for suggesting a successful switching guideline from oral antipsychotics to Abilify Maintena, which can be applicable in clinical practice.

Clinical Study Identifier: NCT03376763

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.